Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH -3.40%46 Earnings per Share (Diluted) is A$-0.47 as of Mar. 2026. GuruFocus rates ASX:AVH with a GF Score™ of 46/100 and a GF Value™ of A$3.22 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 659 Medical Devices & Instruments companies, AVITA Medical ranks worse than 79.67% on this metric.
AVITA Medical's EPS (Basic) for the
three
months ended in Mar. 2026 was A$-0.10.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.47.
AVITA Medical's EPS without NRI for the
three
months ended in Mar. 2026 was A$-0.10.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.47.
During the past 3 years, the average EPS without NRIGrowth Rate was -17.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -4.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -3.10% per year.
During the past 13 years, AVITA Medical's highest 3-Year average EPS without NRI Growth Rate was 70.90% per year. The lowest was -75.90% per year. And the median was 11.05% per year.
AVITA Medical (ASX:AVH) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AVITA Medical Earnings per Share (Diluted) Related Terms
AVITA Medical Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVH vs OWLT, CVRX, STIM: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, AVITA Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's PE Ratio distribution charts can be found below:
* The bar in red indicates where AVITA Medical's PE Ratio falls into.
AVITA Medical Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
AVITA Medical's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of A$-0.47 mean?
AVITA Medical (ASX:AVH) has a Earnings per Share (Diluted) of A$-0.47 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on AVITA Medical and its competitors. According to the industry distribution chart, AVITA Medical ranks #525 out of 659 companies in the Medical Devices & Instruments industry, placing it in the top 79.7%.
Is AVITA Medical's Earnings per Share (Diluted) too high?
AVITA Medical's current Earnings per Share (Diluted) is A$-0.47. Based on the distribution chart, AVITA Medical ranks #525 out of 659 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Earnings per Share (Diluted) compare to OWLT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #525 out of 659 companies for Earnings per Share (Diluted). This places AVITA Medical in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.10, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Earnings per Share (Diluted) is A$-0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.22, compared to a current price of A$1.28 — trading 60.2% below its estimated fair value. The current Earnings per Share (Diluted) is A$-0.47. AVITA Medical's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Earnings per Share (Diluted) is A$-0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$1.28 is trading 60.2% below its estimated GF Value™ of A$3.22.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
Earnings per Share (Diluted): A$-0.47
GF Value™: A$3.22 vs. price of A$1.28 (60.2% below fair value)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
46GF Score
Get the complete analysis for ASX:AVH
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
